特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の肺炎球菌ワクチン市場:成長、動向、および予測

Pneumococcal Vaccines Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 922056
出版日 ページ情報 英文 111 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
世界の肺炎球菌ワクチン市場:成長、動向、および予測 Pneumococcal Vaccines Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年06月01日 ページ情報: 英文 111 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートは世界の肺炎球菌ワクチン市場について調査しており、市場機会や動向、成長および阻害要因、ワクチンタイプ・製品タイプ・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 肺炎予防接種プログラムに関する政府の意識向上プログラム
    • 肺炎球菌による汚染の増加
    • 新規肺炎球菌ワクチンの紹介
  • 市場阻害要因
    • 生産期間が長い
    • 高い生産コスト
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • ワクチンタイプ別
    • 肺炎球菌混合ワクチン
    • 肺炎球菌多糖ワクチン
  • 製品タイプ別
    • Prevnar
    • Synflorix
    • Pneumovax23
  • 流通チャネル別
    • 流通提携企業
    • 非政府組織
    • 政府
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Merck & Co., Inc
    • Serum Institute of India Pvt. Ltd.
    • CSL Ltd.
    • Sanofi Pasteur Inc

第7章 市場機会および今後の動向

目次
Product Code: 67711

The pneumococcal vaccines market studied was projected to grow with a CAGR of nearly 7.5% over the forecast period. The major factor attributing to the growth of the market increasing the prevalence of pneumococcal contaminations.

According to National Center for Immunization and Respiratory Diseases, each year in the United States, more than 250,000 people are hospitalized due to pneumonia and about 50,000 people die from the disease each year in the United States. Furthermore, the growing awareness programs initiated by the government are also boosting the market growth. Rising production of novel vaccines is also another major factor for market growth.

However, the high cost involved in the production of vaccines, and the long duration for the process of production are the major drawbacks for market growth.

Key Market Trends

Pneumococcal conjugate vaccine segment expected to dominate the market throughout the forecast period

A conjugate vaccine is a substance that is comprised of a polysaccharide antigen fused to a carrier molecule. This improves the stability and efficacy of the vaccine. The Pneumococcal conjugate vaccine segment is a major contributor to the global pneumonia vaccine market, this is credited to the wide age group that is covered by this type of vaccine. These vaccines can vaccinate infants and children from 6 weeks to 5 years of age to prevent pneumonia and acute otitis media.

Furthermore, the conjugate vaccine stimulates immunological memory and reduces asymptomatic delivery of the bacteria, resulting in marked group immunity. Hence this segment has a higher market share.

North America Dominates the Market and Asia Pacific is Expected to grow at a higher CAGR in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. Factors such as the presence of key players and established healthcare infrastructure are the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. The Asia Pacific is the fastest-growing region due to the high prevalence of pneumococcal infection. The major countries of this region have the highest-burden in the world and hence there is more need for vaccination to prevent the disease.

Competitive Landscape

The pneumococcal vaccine market is highly consolidated and consists of a few players. Some of the companies which are currently dominating the market are GlaxoSmithKline plc, Pfizer Inc., CSL Ltd., Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Sanofi Pasteur Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing government awareness programs regarding pneumonia immunization program
    • 4.2.2 Rising prevalence of pneumococcal contaminations
    • 4.2.3 Introduction of novel pneumococcal vaccines
  • 4.3 Market Restraints
    • 4.3.1 Long duration for the production
    • 4.3.2 High cost of production
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Vaccine Type
    • 5.1.1 Pneumococcal conjugate vaccine
    • 5.1.2 Pneumococcal polysaccharide vaccine
  • 5.2 By Product Type
    • 5.2.1 Prevnar 13
    • 5.2.2 Synflorix
    • 5.2.3 Pneumovax23
  • 5.3 By Distribution Channel
    • 5.3.1 Distribution partner companies
    • 5.3.2 Non-governmental Organizations
    • 5.3.3 Government Authorities
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline plc
    • 6.1.2 Pfizer Inc.
    • 6.1.3 Merck & Co., Inc
    • 6.1.4 Serum Institute of India Pvt. Ltd.
    • 6.1.5 CSL Ltd.
    • 6.1.6 Sanofi Pasteur Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS